Legend Biotech Corporation EV/Revenue LTM
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| EV/Revenue LTM | 61.2x | 73.5x | 61.8x | 42.2x |
Legend Biotech Corporation (LEGN) EV/Revenue LTM comparison analysis
General
LTM EV/Revenue LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
LEGN key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 23.6 0.0% | 49.1 108.2% | 57.3 16.5% | 75.7 32.2% | 89.8 18.7% | 117.0 30.3% | 285.1 143.7% |
| Cost of Goods Sold (COGS) | (0.1) | 0.0 | 0.0 | 232.2 | 313.3 | 65.4 | 144.2 |
% margin | 23.7 100.4% | 49.1 100.0% | 57.3 100.0% | (156.5) (206.8%) | (223.6) (249.0%) | 51.6 44.1% | 140.9 49.4% |
| Operating Expenses | 9.6 | 64.2 | 192.6 | 304.9 | 462.8 | 509.7 | 140.9 |
| Research & Development Expenses (R&D) | 8.2 | 60.6 | 161.9 | 232.2 | 313.3 | 335.6 | 382.2 |
| Selling, General & Administrative Expenses (SG&A) | 1.4 | 3.9 | 32.4 | 72.7 | 149.5 | 174.0 | 200.9 |
% margin | 13.8 58.4% | (1.5) (3.1%) | (130.9) (228.5%) | (313.3) (414.1%) | (393.0) (437.7%) | (455.8) (389.6%) | (439.5) (154.1%) |
| Interest Income | 0.0 | 6.2 | 4.6 | 2.9 | 1.0 | 8.2 | 54.5 |
| Interest Expense | 0.0 | 0.1 | 0.2 | 4.2 | 0.9 | 10.8 | 21.8 |
| Pre-tax Income | 13.8 | (1.6) | (130.4) | (307.6) | (386.2) | (445.7) | (520.1) |
% effective tax rate | 4.5 32.3% | 1.2 (72.3%) | 2.6 (2.0%) | (4.1) 1.3% | 0.0 (0.0%) | 0.6 (0.1%) | (1.9) 0.4% |
% margin | 9.4 39.7% | (2.8) (5.7%) | (133.0) (232.2%) | (303.5) (401.0%) | (386.2) (430.1%) | (446.3) (381.5%) | (518.3) (181.8%) |
| EPS | 0.07 | (0.03) | (1.01) | (2.57) | (2.74) | (2.81) | (2.94) |
| Diluted EPS | 0.07 | (0.03) | (1.01) | (2.57) | (2.74) | (2.81) | (2.94) |
% margin | 14.1 59.6% | 0.1 0.3% | (124.9) (218.1%) | (294.1) (388.7%) | (392.4) (437.0%) | (416.5) (356.0%) | (477.9) (167.6%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Legend Biotech Corporation's EV/Revenue LTM?
As of today, Microsoft Corp's last 12-month EV/Revenue LTM is 17.6x, based on the financial report for Sep 27, 2024 (Q3’2024). The average annual EV/Revenue LTM for Legend Biotech Corporation have been 60.7x over the past three years, and 55.0x over the past five years.
2) Is Legend Biotech Corporation's EV/Revenue LTM Good?
As of today, Legend Biotech Corporation's EV/Revenue LTM is 17.6x, which is higher than industry median of 3.7x. It indicates that Legend Biotech Corporation's EV/Revenue LTM is Bad.